HALO Key Statistics, Chart & Performance
The current stock price of HALO is 80.86 USD. In the past month the price increased by 11.05%. In the past year, price increased by 38.07%.
HALO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to HALO. When comparing the yearly performance of all stocks, HALO is one of the better performing stocks in the market, outperforming 84.13% of all stocks.
HALO Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to HALO. HALO scores excellent on profitability, but there are some minor concerns on its financial health.
HALO Financial Highlights
Over the last trailing twelve months HALO reported a non-GAAP Earnings per Share(EPS) of 5.63. The EPS increased by 48.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 47.91% | ||
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| Debt/Equity | 1.59 |
HALO Forecast & Estimates
15 analysts have analysed HALO and the average price target is 79.56 USD. This implies a price decrease of -1.61% is expected in the next year compared to the current price of 80.86.
For the next year, analysts expect an EPS growth of 58.04% and a revenue growth 38.12% for HALO
HALO Ownership
HALO Latest News, Press Relases and Analysis
HALO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.44 | 394.585B | ||
| AMGN | AMGEN INC | 16.29 | 202.372B | ||
| GILD | GILEAD SCIENCES INC | 16.8 | 188.186B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.99 | 119.469B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.69 | 82.007B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.47 | 42.275B | ||
| INSM | INSMED INC | N/A | 31.892B | ||
| NTRA | NATERA INC | N/A | 29.062B | ||
| BIIB | BIOGEN INC | 12.59 | 28.432B | ||
| INCY | INCYTE CORP | 12.78 | 21.405B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HALO
Company Profile
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 350 full-time employees. The company went IPO on 2003-01-30. The firm's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. The company also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED. The company also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
Company Info
HALOZYME THERAPEUTICS INC
12390 El Camino Real
San Diego CALIFORNIA 92121-1345 US
CEO: Helen I. Torley
Employees: 350
Phone: 18587948889
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you describe the business of HALOZYME THERAPEUTICS INC?
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 350 full-time employees. The company went IPO on 2003-01-30. The firm's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. The company also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED. The company also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
Can you provide the latest stock price for HALOZYME THERAPEUTICS INC?
The current stock price of HALO is 80.86 USD. The price increased by 0.47% in the last trading session.
What is the dividend status of HALOZYME THERAPEUTICS INC?
HALO does not pay a dividend.
What is the ChartMill technical and fundamental rating of HALO stock?
HALO has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
On which exchange is HALO stock listed?
HALO stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for HALO stock?
The PE ratio for HALOZYME THERAPEUTICS INC (HALO) is 14.36. This is based on the reported non-GAAP earnings per share of 5.63 and the current share price of 80.86 USD.
Is HALOZYME THERAPEUTICS INC (HALO) expected to grow?
The Revenue of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 38.12% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.